SCHEMBL13552995

SCHEMBL13552995

O=C(Nc1cccnc1)Nc1ccc(Cl)c(-c2nccc3ccccc23)c1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 7/20 0.54
▸ KMT2A Q03164 7/20 0.54
▸ HTT P42858 4/20 0.54
▸ LMNA P02545 3/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ RAB9A P51151 3/20 0.51
▸ MAPT P10636 4/20 0.50
▸ ALDH1A1 P00352 3/20 0.50
▸ KDR P35968 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ MAPK1 P28482 2/20 0.47
▸ TRPV1 Q8NER1 1/20 0.47
▸ ATM Q13315 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ TAAR1 Q96RJ0 1/20 0.46
▸ MTOR P42345 1/20 0.46
▸ IMPDH2 P12268 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13044323 0.90 MAPT (0.48) MEN1KMT2AHTTLMNANPC1
SCHEMBL13552972 0.89 ALDH1A1 (0.54) MEN1KMT2AHTTLMNATP53
SCHEMBL14707505 0.88 SMARCA2 (0.52) MEN1KMT2ALMNANPC1RAB9A
SCHEMBL13554607 0.87 MEN1 (0.46) MEN1KMT2AHTTLMNANPC1
SCHEMBL13552857 0.86 NPC1 (0.61) MEN1KMT2AHTTLMNANPC1
SCHEMBL13044270 0.86 CSF1R (0.59) MEN1KMT2ANPC1RAB9A
SCHEMBL13552722 0.85 MEN1 (0.56) MEN1KMT2AHTTLMNANPC1
SCHEMBL13552997 0.84 NPC1 (0.63) MEN1KMT2ALMNANPC1RAB9A
SCHEMBL13553004 0.82 KDR (0.58) KDRTRPV1
SCHEMBL13553001 0.82 PTPN7 (0.45) MEN1KMT2ALMNANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
US-9345699-B2 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling NANTBIOSCIENCE, INC. (US) 2016-05-24 — — US disclosed
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2014-03-13 — — US disclosed
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2014-03-13 — — US disclosed
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2013-02-21 — — US disclosed
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS ABRAXIS BIOSCIENCE, LLC (US) 2013-02-21 — — US disclosed
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling CALIFORNIA CAPITAL EQUITY, LLC (US) 2012-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045240-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS SHH, GLI1, SMO MEN1 1016/4885KMT2A 2378/4885HTT 146/4885
US-20120270858-A1 Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling SHH, GLI1, SMO MEN1 1456/4885KMT2A 1798/4885HTT 375/4885
US-20140072630-A1 COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS SHH, GLI1, SMO MEN1 1016/4885KMT2A 2378/4885HTT 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback